Kidney Cancer

Previously treated patients with advanced renal cell carcinoma saw a higher overall survival rate with Cabometyx when compared to those on Afinitor, according to a phase 3 study.

In the longest follow-up of an anti-PD-1 immunotherapy in RCC, about one-third of the patients treated with single-agent Opdivo are still alive four and five years later.

What are the next steps for immunotherapy in RCC? CURE spoke with Mark Ball to find out.

After a phase 2 study, Lenvima and Afinitor gained FDA approval for the treatment of renal cell carcinoma.

“This is a small-site, single-arm study, but these preliminary data are encouraging,” says lead study author Roberto Pili. “It suggests that this combination of an HDAC inhibitor can induce a greater benefit with an immunotherapy — in this case, IL-2.”

Despite advances in treatment for bladder cancer and RCC, there is still an unmet need for navigating biomarkers that will offer insight as to which patients will respond best to treatment.

“There are a lot of drugs, many targets, and still no cures,” says Figlin. “There is still an unmet need, despite the plethora of agents that have been approved in this space.”

As treatments for kidney cancer continue to evolve, oncologists, surgeons and patients are faced with a number of questions.

The field of immunotherapy has been revitalized thanks to the approval of checkpoint inhibitors, and according to Mario Sznol, this could prove beneficial to patients with RCC.

The Kidney Cancer Association was part of the force behind the many kidney cancer advancements in the past decade, but they won't stop there.

New pathways for secondary-line treatment are coming available to patients with advanced renal cell carcinoma.

Cometriq elicited a statistically significant improvement in survival compared with Afinitor as a treatment for patients with advanced renal cell carcinoma following progression on one prior therapy.

Cometriq significantly improved progression-free survival versus Afinitor in patients with renal cell carcinoma regardless of the degree of metastases, type or number of prior treatments, or patient risk status.

The approval was based on an extension in overall survival (OS) in the CheckMate-025 trial.

As part of this program, the FDA plans to take action on the drug's application within six months instead of the standard 10 months under regular review.

The breakthrough therapy designation will expedite the development and review of Opdivo in advanced renal cell carcinoma.

By empowering the body to fight breast and renal cancers, immunotherapies are poised to improve the treatment landscape.

Better treatment and follow-up are being credited with a reduction in the likelihood that survivors of childhood cancers will later die of illnesses caused by their therapy, such as new malignancies or cardiac or lung disease.

Research presented at ASCO shows late effects of childhood cancer treatment lessening.

In a recent study, researchers looked at statins and survival outcomes, along with potential side effects, in patients with metastatic renal cell carcinoma.

NORD was founded in 1983 by parents of children with rare diseases. Over the past 30 years, it has become a powerful advocacy voice for all patients with rare diseases, including cancer.

Project: EveryChild is collecting biologic samples, such as blood, tissue and other specimens, from children undergoing treatment.

Blood Pressure Meds Help Hypertensive Patients With Kidney Cancer

Updates from ASCO's Genitourinary Cancers Symposium.

Goals and milestone recognitions may help children with cancer get through treatment a little easier.

Long-term and late effects from toxic regimens from childhood cancer treatments include heart damage, lung problems and infertility.

Pediatric cancer treatment has come a long way, but health problems persist in survivorship.

A recent report notes that certain health issues observed in young adult survivors are typically seen in much older individuals.

Childhood and young adult cancer survivors need fertility preservation information, but are they getting it from their oncologists?

A kid can bring out the best in people.